Sentences with phrase «cell technology in»

They also have plans to offer fuel - cell technology in their road cars.

Well, four of the big plants that make corn syrup use mercury - cell technology in the production of caustic soda, an ingredient used in the corn conversion process.

The Single Cell Genomics Team at CNAG is dedicated to advance genome research of single cells and targets to enable the researchers to use single cell technology in scalable and affordable manner.

Biologist Robert Lanza of Advanced Cell Technology in Worcester, Mass., reports his team's findings in this week's issue of the journal Nature.

The new advance comes from the laboratory of biologist Robert Lanza of Advanced Cell Technology in Worcester, Mass..

«This is an impressive study» which «clears up a longstanding scientific question,» says Robert Lanza, medical director of Advanced Cell Technology in Worcester, Massachusetts.

«It's a great success,» says Philip Damiani, a reproductive physiologist at Advanced Cell Technology in Worcester, Massachusetts.

«Regulatory agencies would be very concerned that ChR2 DNA was found in tissues outside of the treated eye,» says Robert Lanza, of Advanced Cell Technology in Worcester, Massachusetts.

In 2008 a group of medical researchers led by Robert Lanza at Advanced Cell Technology in Worcester, Massachusetts, reported another leap: They discovered a way to avoid destroying the embryo by deriving an entire stem cell line from a single embryonic cell.

Something as simple as an unsterilized milk bottle may have transmitted the bug, say researchers at Advanced Cell Technology in Worcester, Massachusetts, which created Noah.

Scientists at the biotechnology firm Advanced Cell Technology in Worcester, Mass., have generated a more abundant source of RPE cells.

Stemagen's team says that's next, but Robert Lanza of Advanced Cell Technology in Worcester, Massachusetts, doubts the researchers could do it with the embryos they have created so far.

«The time is coming when we'll repair heart tissue after a heart attack and restore blood flow to limbs that would otherwise be amputated,» says stem cell researcher Robert Lanza of Advanced Cell Technology in Massachusetts.

«It's premature to abandon ESCs until we understand what's going on with iPSCs,» says Robert Lanza, chief scientist at Advanced Cell Technology in Massachusetts.

The researchers — James Robl, a developmental biologist and his colleagues at the University of Massachusetts at Amherst, and Steve Stice at Advanced Cell Technology in Worcester, Massachusetts — inserted a marker gene fused with a gene for resistance to the chemical neomycin into a culture of connective tissue cells called fibroblasts.

To get more cells, researchers from Advanced Cell Technology in Worcester, Mass., grew clusters of human embryonic cells in a precise cocktail of growth factors and other cell - regulating chemicals that took several years to work out, says Robert Lanza, the firm's vice president of research and scientific development.

Stem cell expert Robert Lanza, who heads scientific research at Advanced Cell Technology in Massachusetts, calls the research an «exciting, novel idea.»

«We've been hearing about their potential for more than a decade, but the results have always been in mice and rats, and no one has shown they're safe or effective in humans long term,» says Robert Lanza of Advanced Cell Technology in Marlborough, Massachusetts, the company that carried out the stem cell intervention.

Honda and General Motors are investing $ 85 million in producing new fuel cell technology in 2020.

But Toyota is helping spur infrastructure development for the Mirai, an effort that happily means helping along fuel - cell technology in general.

Not exact matches

• NanoCellect Biomedical, a San Diego - based developer of microfluidic cell sorting technologies for cell - based assays, raised $ 10 million in series B funding.

The Small Business Administration has invested more than $ 1.5 million in fuel - cell technology innovation.

The technology's possibilities are staggering — in theory, allowing medical scientists to do everything from cure genetic disorders like sickle cell disease to identify gene targets for combating HIV.

They would include jobs in research and development, manufacturing and sales and would be focused on the company's next - generation cell technology.

«If you're vulnerable and isolated, the more important that cell phone becomes for you,» says Mark Latonero, a fellow at the Data & Society Research Institute in New York, who has studied technology and human trafficking.

Hydrogen fuel cells are a zero - emission technology, but the fueling infrastructure is extremely rare in the United States.

Cancer - focused CRISPR technology involves taking a set of molecular shears and the guiding molecule Cas9 in order to cut out unwanted genes in immune cells that may help proliferate cancers.

Bentley - based information technology company ISA Technologies has become the first organisation in the southern hemisphere to use revolutionary new IBM Cell chip technology for high performance computing and visualisation.

If the technology had been available, I would probably have been one of those poor souls sitting on the beach with a BlackBerry in one hand, a cell phone in the other, and a computer on my lap.

Technology by Cellectis allows cellular engineering, and a human trial of the company's work in editing blood cells will be presented at the upcoming American Society of Hematology.

What else it offers: The car may not be available for purchased, but the hydrogen fuel cell technology may make an appearance in other Toyota vehicles.

«There's absolutely no reason that every patient with a B - cell malignancy shouldn't be cured with this technology,» Juno CFO Steve Harr told Fortune in an interview.

A veteran of digital imaging technology, in 1999 he founded Quantitative Imaging Corp. (QImaging), a manufacturer of digital cameras for scientific and industrial uses — the kind, for example, that can detect microscopic, early - stage cancer cells.

In December, SQZ partnered with global pharma firm and cancer treatment leader F. Hoffmann - La Roche in a deal that could be worth $ 500 million or more — a large undisclosed upfront payment, and additional sums when SQZ meets certain milestones — to speed up the development of its technology specifically to inject a person's immune cells with a protein to activate a «killer T» cell response to fight off canceIn December, SQZ partnered with global pharma firm and cancer treatment leader F. Hoffmann - La Roche in a deal that could be worth $ 500 million or more — a large undisclosed upfront payment, and additional sums when SQZ meets certain milestones — to speed up the development of its technology specifically to inject a person's immune cells with a protein to activate a «killer T» cell response to fight off cancein a deal that could be worth $ 500 million or more — a large undisclosed upfront payment, and additional sums when SQZ meets certain milestones — to speed up the development of its technology specifically to inject a person's immune cells with a protein to activate a «killer T» cell response to fight off cancer.

«This technology will allow us to paint a whole chromosome and look at it live and really follow it... as it goes through developmental transitions, for example in an embryo,» study co-author Rebecca Heald, a molecular and cell biologist at UC Berkeley, said in a statement.

«Satellite technology can help reach Americans who live in rural or hard - to - serve places where fiber optic cables and cell towers do not reach,» Pai said in a statement.

That's attached to the progress of sequencing technology, the ability to edit cells, and other gene editing approaches have been transformative in the immunotherapy world in recent years.

«Satellite technology can help reach Americans who live in rural or hard - to - serve places where fiber optic cables and cell towers do not...

T - Mobile, Verizon, and other carriers have been adding new technology and more cell phone sites to improve efficiency and capacity in their networks.

The majority of the fuel - cell industry is rooted in the Northeast, but fuel - cell businesses there have only been cooperating for the past decade or so, says Joel M. Rinebold, director of energy initiatives at the Connecticut Center for Advanced Technology, the East Hartford, Conn. - based organization that oversees the cluster.

Center said hydrogen fuel cells are the «ultimate technology for the long term» because the cars boast faster re-fill times, perform better in colder weather, and offer longer ranges than electric vehicles.

The fuel cell technology company posted revenue of $ 20.1 million in the period, which also did not meet Street forecasts.

Announced a worldwide collaboration with Sangamo Therapeutics, Inc. (Sangamo) using Sangamo's zinc finger nuclease technology platform for the development of next - generation ex vivo cell therapies in oncology.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline.

From microprocessors to printers, operating systems to cell phone handsets, recent advances in technology have turned IT into a giant part of the domestic and global economies.

Future Meat Technologies is working to commercialize a manufacturing technology for fat and muscle cells that was first developed in the laboratories of the Hebrew University of Jerusalem.

Going forward we are able to leverage advances from investments in adjacent industries to continue to advance our technology — from LED lighting, to plastic moulding, to new multi-junction cells for the satellite industry.»

BioNTech, which has around 700 employees at sites in Germany — more than any other unlisted biotech firm in Europe — is also working on other cancer - fighting technologies, including antibodies, cell therapies and small molecules.

The following month, SolarCity, having determined that Silevo would not achieve two of its three production and technology milestones, decided that it had to bring in an outside partner, Panasonic, to help bear the costs and to take over solar - cell manufacturing.